🇺🇸 FDA
Patent

US 10494435

Human monoclonal antibodies specific for CD22

granted A61KA61K2039/505A61K38/164

Quick answer

US patent 10494435 (Human monoclonal antibodies specific for CD22) held by The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services
Grant date
Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K38/164, A61K38/45, A61K39/00